MSCap™ Technology — The Next Evolution in mRNA Capping
Enhanced capping efficiency, improved expression, and extended stability — designed to unlock the full potential of mRNA therapeutics.
MSCap™ Structure
MSCap™ Technology: Redefining mRNA Translation Efficiency
MSCap™ is Elonova’s proprietary next-generation 5′ cap analog platform designed to overcome the key limitations of conventional mRNA capping systems.
Through advanced chemical design and optimized hydrophobic interactions, MSCap™ ensures higher capping efficiency, improved translation initiation, and sustained protein expression both in vitro and in vivo.
Technology Overview
MSCap™: Smarter Chemistry for Stronger mRNA
MSCap™ is Elonova’s proprietary 5′ cap analog platform that optimizes mRNA performance from synthesis to expression.
By precisely tuning the cap chemistry, MSCap™ enhances capping efficiency, simplifies purification, and delivers long-lasting, stable mRNA translation with balanced immune activation.
Core Advantages
The hydrophobic functional group allows clean HPLC separation between capped and uncapped RNA, ensuring high purity.
Co-transcriptional capping yields consistently higher capping rates compared to conventional analogs.
Promotes efficient ribosome recruitment and translation initiation for stronger protein output.
Sustained mRNA activity and protein expression confirmed in multiple preclinical models.
Minimizes unwanted innate immune activation while maintaining desirable immune balance.
Different MSCap analogs provide slightly varied innate immune characteristics, enabling tailored immunomodulation for specific therapeutic needs.
Preclinical studies showed notable antitumor effects and sustained expression with MSCap-based mRNA constructs.
High Capping Efficiency
MSCap™: >93% capping efficiency
- Compatible with co-transcriptional workflows
Validated : Standard IVT process compatible
Superior HPLC Separation
Easy separation
- Reduced dsRNA signature
- Clean separation from uncaped mRNAs
- MSCap’ hydrophobicity induce clear seperation
High Translation efficiency
Higher expression vs standard cap1
- Invitro validation : 1.65 - 2.5 × higher protein expression
In vivo : Prolonged luciferase window
Broad Applications Across the mRNA Landscape
MSCap™ technology enhances both the efficiency and reliability of mRNA production for a wide range of applications — from research use to clinical development.
- Infectious Disease Vaccines
-
RSV, CMV, and other multivalent antigen designs
- Cancer Immunotherapy
-
Enhanced antigen and cytokine expression for stronger immune responses
- Gene & Cell Therapy Support
-
Maximized transgene expression in ex vivo and in vivo systems
- Next-generation Formats
-
Self-amplifying mRNA and novel delivery platforms
Manufacturing Benefits
-
Compatible with T7 RNA polymerase and SP6 RNA polymerase IVT systems
-
Works with modified nucleotides (Ψ, m¹Ψ, 5-mC, F-CTP, etc.)
-
Seamless integration into LNP, polymeric, or peptide delivery systems
Ex-vivo data analysis
Collaborate
with Us
Elonova welcomes partnerships with biotechnology and pharmaceutical
companies seeking to advance next-generation mRNA therapeutics.
We offer technical evaluation kits, process transfer support, and joint
development programs for both RUO and clinical-scale applications.